143 related articles for article (PubMed ID: 6099688)
21. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
Guigoni C; Doudnikoff E; Li Q; Bloch B; Bezard E
Neurobiol Dis; 2007 May; 26(2):452-63. PubMed ID: 17350277
[TBL] [Abstract][Full Text] [Related]
22. Parkinson's disease: nigral receptor changes support peptidergic role in nigrostriatal modulation.
Uhl GR; Hackney GO; Torchia M; Stranov V; Tourtellotte WW; Whitehouse PJ; Tran V; Strittmatter S
Ann Neurol; 1986 Aug; 20(2):194-203. PubMed ID: 3019228
[TBL] [Abstract][Full Text] [Related]
23. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC
Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445
[TBL] [Abstract][Full Text] [Related]
24. [The life history of brain dopamine].
Hornykiewicz O
Wien Klin Wochenschr; 1985 Apr; 97(8):350-4. PubMed ID: 2986364
[TBL] [Abstract][Full Text] [Related]
25. Synaptic and non-synaptic striatal dopamine D2 receptors: possible implications in normal and pathological behaviour.
Korf J; Loopuijt LD
Acta Morphol Neerl Scand; 1988-1989; 26(2-3):177-90. PubMed ID: 2908162
[TBL] [Abstract][Full Text] [Related]
26. Disturbances in neurotransmission processes in aging and age-related diseases.
Ossowska K
Pol J Pharmacol; 1993; 45(2):109-31. PubMed ID: 8401765
[TBL] [Abstract][Full Text] [Related]
27. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
28. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
[TBL] [Abstract][Full Text] [Related]
29. Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter.
Calon F; Lavertu N; Lemieux AM; Morissette M; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
Synapse; 2001 Jun; 40(3):225-34. PubMed ID: 11304760
[TBL] [Abstract][Full Text] [Related]
30. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
Porritt MJ; Batchelor PE; Howells DW
Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
[TBL] [Abstract][Full Text] [Related]
31. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
St-Hilaire M; Landry E; Lévesque D; Rouillard C
Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
[TBL] [Abstract][Full Text] [Related]
32. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
Lee J; Zhu WM; Stanic D; Finkelstein DI; Horne MH; Henderson J; Lawrence AJ; O'Connor L; Tomas D; Drago J; Horne MK
Brain; 2008 Jun; 131(Pt 6):1574-87. PubMed ID: 18487277
[TBL] [Abstract][Full Text] [Related]
33. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
[TBL] [Abstract][Full Text] [Related]
34. Peculiarities of L: -DOPA treatment of Parkinson's disease.
Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
[TBL] [Abstract][Full Text] [Related]
35. NMDA receptors modulate dopamine loss due to energy impairment in the substantia nigra but not striatum.
Zeevalk GD; Manzino L; Sonsalla PK
Exp Neurol; 2000 Feb; 161(2):638-46. PubMed ID: 10686083
[TBL] [Abstract][Full Text] [Related]
36. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson's disease.
Collier TJ; Sortwell CE; Elsworth JD; Taylor JR; Roth RH; Sladek JR; Redmond DE
J Comp Neurol; 2002 Jan; 442(4):320-30. PubMed ID: 11793337
[TBL] [Abstract][Full Text] [Related]
37. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
Hirsch EC
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138
[TBL] [Abstract][Full Text] [Related]
38. Automimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia.
Abramsky O; Litvin Y
Perspect Biol Med; 1978; 22(1):104-14. PubMed ID: 733451
[TBL] [Abstract][Full Text] [Related]
39. Dopamine D-1 receptors in the parkinsonian brain.
Rinne JO; Rinne JK; Laakso K; Lönnberg P; Rinne UK
Brain Res; 1985 Dec; 359(1-2):306-10. PubMed ID: 2934111
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Parkinson's disease: problems with a progressing disease.
Rinne UK
J Neural Transm; 1981; 51(1-2):161-74. PubMed ID: 7264627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
